Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26


Piezo1 is as a novel trefoil factor family 1 binding protein that promotes gastric cancer cell mobility in vitro.

Yang XN, Lu YP, Liu JJ, Huang JK, Liu YP, Xiao CX, Jazag A, Ren JL, Guleng B.

Dig Dis Sci. 2014 Jul;59(7):1428-35. doi: 10.1007/s10620-014-3044-3. Epub 2014 May 6.


Pyruvate kinase M2 plays a dual role on regulation of the EGF/EGFR signaling via E-cadherin-dependent manner in gastric cancer cells.

Wang LY, Liu YP, Chen LG, Chen YL, Tan L, Liu JJ, Jazag A, Ren JL, Guleng B.

PLoS One. 2013 Jun 28;8(6):e67542. doi: 10.1371/journal.pone.0067542. Print 2013.


The silencing of Pokemon attenuates the proliferation of hepatocellular carcinoma cells in vitro and in vivo by inhibiting the PI3K/Akt pathway.

Lin CC, Zhou JP, Liu YP, Liu JJ, Yang XN, Jazag A, Zhang ZP, Guleng B, Ren JL.

PLoS One. 2012;7(12):e51916. doi: 10.1371/journal.pone.0051916. Epub 2012 Dec 26.


ECHS1 acts as a novel HBsAg-binding protein enhancing apoptosis through the mitochondrial pathway in HepG2 cells.

Xiao CX, Yang XN, Huang QW, Zhang YQ, Lin BY, Liu JJ, Liu YP, Jazag A, Guleng B, Ren JL.

Cancer Lett. 2013 Mar 1;330(1):67-73. doi: 10.1016/j.canlet.2012.11.030. Epub 2012 Nov 23.


Status quo of chronic liver diseases, including hepatocellular carcinoma, in Mongolia.

Jazag A, Puntsagdulam N, Chinburen J.

Korean J Intern Med. 2012 Jun;27(2):121-7. doi: 10.3904/kjim.2012.27.2.121. Epub 2012 May 31. Review.


HBsAg inhibits the translocation of JTB into mitochondria in HepG2 cells and potentially plays a role in HCC progression.

Liu YP, Yang XN, Jazag A, Pan JS, Hu TH, Liu JJ, Guleng B, Ren JL.

PLoS One. 2012;7(5):e36914. doi: 10.1371/journal.pone.0036914. Epub 2012 May 15.


Aplasia ras homolog member I is downregulated in gastric cancer and silencing its expression promotes cell growth in vitro.

Tang HL, Hu YQ, Qin XP, Jazag A, Yang H, Yang YX, Yang XN, Liu JJ, Chen JM, Guleng B, Ren JL.

J Gastroenterol Hepatol. 2012 Aug;27(8):1395-404. doi: 10.1111/j.1440-1746.2012.07146.x.


Double-stranded RNA-activated protein kinase inhibits hepatitis C virus replication but may be not essential in interferon treatment.

Chang JH, Kato N, Muroyama R, Taniguchi H, Guleng B, Dharel N, Shao RX, Tateishi K, Jazag A, Kawabe T, Omata M.

Liver Int. 2010 Feb;30(2):311-8. doi: 10.1111/j.1478-3231.2009.02144.x. Epub 2009 Oct 16.


Potential contribution of tumor suppressor p53 in the host defense against hepatitis C virus.

Dharel N, Kato N, Muroyama R, Taniguchi H, Otsuka M, Wang Y, Jazag A, Shao RX, Chang JH, Adler MK, Kawabe T, Omata M.

Hepatology. 2008 Apr;47(4):1136-49. doi: 10.1002/hep.22176.


The molecular biology of pancreatic cancer.

Abramson MA, Jazag A, van der Zee JA, Whang EE.

Gastrointest Cancer Res. 2007;1(4 Suppl 2):S7-S12.


Overexpression of HMGA1 promotes anoikis resistance and constitutive Akt activation in pancreatic adenocarcinoma cells.

Liau SS, Jazag A, Ito K, Whang EE.

Br J Cancer. 2007 Mar 26;96(6):993-1000. Epub 2007 Mar 6.


Smad4 is essential for down-regulation of E-cadherin induced by TGF-beta in pancreatic cancer cell line PANC-1.

Takano S, Kanai F, Jazag A, Ijichi H, Yao J, Ogawa H, Enomoto N, Omata M, Nakao A.

J Biochem. 2007 Mar;141(3):345-51. Epub 2007 Feb 14.


Smoothened gene mutations found in digestive cancer have no aberrant Hedgehog signaling activity.

Guleng B, Tateishi K, Ohta M, Asaoka Y, Jazag A, Lin LJ, Tanaka Y, Tada M, Seto M, Kanai F, Kawabe T, Omata M.

J Gastroenterol. 2006 Dec;41(12):1238-9. Epub 2007 Feb 6. No abstract available.


Dysregulated expression of stem cell factor Bmi1 in precancerous lesions of the gastrointestinal tract.

Tateishi K, Ohta M, Kanai F, Guleng B, Tanaka Y, Asaoka Y, Tada M, Seto M, Jazag A, Lianjie L, Okamoto M, Isayama H, Tada M, Yoshida H, Kawabe T, Omata M.

Clin Cancer Res. 2006 Dec 1;12(23):6960-6.


Hepatitis C virus core protein is a potent inhibitor of RNA silencing-based antiviral response.

Wang Y, Kato N, Jazag A, Dharel N, Otsuka M, Taniguchi H, Kawabe T, Omata M.

Gastroenterology. 2006 Mar;130(3):883-92.


TRAIL-induced cell death cooperates with IFN-gamma activation in the graft-versus-tumor effect against colon tumors.

Tateishi K, Ohta M, Guleng B, Kanai F, Tanaka Y, Asaoka Y, Jazag A, Imamura J, Imamura T, Ijichi H, Ikenoue T, Kawakami T, Fukushima Y, Washida M, Sata M, Miyagishi M, Taira K, Yoshida H, Kawabe T, Omata M.

Int J Cancer. 2006 May 1;118(9):2237-46.


Absence of PIK3CA hotspot mutations in hepatocellular carcinoma in Japanese patients.

Tanaka Y, Kanai F, Tada M, Asaoka Y, Guleng B, Jazag A, Ohta M, Ikenoue T, Tateishi K, Obi S, Kawabe T, Yokosuka O, Omata M.

Oncogene. 2006 May 11;25(20):2950-2.


p53-Independent negative regulation of p21/cyclin-dependent kinase-interacting protein 1 by the sonic hedgehog-glioma-associated oncogene 1 pathway in gastric carcinoma cells.

Ohta M, Tateishi K, Kanai F, Watabe H, Kondo S, Guleng B, Tanaka Y, Asaoka Y, Jazag A, Imamura J, Ijichi H, Ikenoue T, Sata M, Miyagishi M, Taira K, Tada M, Kawabe T, Omata M.

Cancer Res. 2005 Dec 1;65(23):10822-9.


The hepatitis B virus X protein enhances AP-1 activation through interaction with Jab1.

Tanaka Y, Kanai F, Ichimura T, Tateishi K, Asaoka Y, Guleng B, Jazag A, Ohta M, Imamura J, Ikenoue T, Ijichi H, Kawabe T, Isobe T, Omata M.

Oncogene. 2006 Jan 26;25(4):633-42.


Cancer-derived VEGF plays no role in malignant ascites formation in the mouse.

Guleng B, Tateishi K, Kanai F, Jazag A, Ohta M, Asaoka Y, Ijichi H, Tanaka Y, Imamura J, Ikenoue T, Fukushima Y, Morikane K, Miyagishi M, Taira K, Kawabe T, Omata M.

World J Gastroenterol. 2005 Sep 21;11(35):5455-9.


Single small-interfering RNA expression vector for silencing multiple transforming growth factor-beta pathway components.

Jazag A, Kanai F, Ijichi H, Tateishi K, Ikenoue T, Tanaka Y, Ohta M, Imamura J, Guleng B, Asaoka Y, Kawabe T, Miyagishi M, Taira K, Omata M.

Nucleic Acids Res. 2005 Aug 19;33(15):e131.


Blockade of the stromal cell-derived factor-1/CXCR4 axis attenuates in vivo tumor growth by inhibiting angiogenesis in a vascular endothelial growth factor-independent manner.

Guleng B, Tateishi K, Ohta M, Kanai F, Jazag A, Ijichi H, Tanaka Y, Washida M, Morikane K, Fukushima Y, Yamori T, Tsuruo T, Kawabe T, Miyagishi M, Taira K, Sata M, Omata M.

Cancer Res. 2005 Jul 1;65(13):5864-71.


Functional analysis of PIK3CA gene mutations in human colorectal cancer.

Ikenoue T, Kanai F, Hikiba Y, Obata T, Tanaka Y, Imamura J, Ohta M, Jazag A, Guleng B, Tateishi K, Asaoka Y, Matsumura M, Kawabe T, Omata M.

Cancer Res. 2005 Jun 1;65(11):4562-7.


Functional consequences of mutations in a putative Akt phosphorylation motif of B-raf in human cancers.

Ikenoue T, Kanai F, Hikiba Y, Tanaka Y, Imamura J, Ohta M, Jazag A, Guleng B, Asaoka Y, Tateishi K, Kawakami T, Matsumura M, Kawabe T, Omata M.

Mol Carcinog. 2005 May;43(1):59-63.


Smad4 silencing in pancreatic cancer cell lines using stable RNA interference and gene expression profiles induced by transforming growth factor-beta.

Jazag A, Ijichi H, Kanai F, Imamura T, Guleng B, Ohta M, Imamura J, Tanaka Y, Tateishi K, Ikenoue T, Kawakami T, Arakawa Y, Miyagishi M, Taira K, Kawabe T, Omata M.

Oncogene. 2005 Jan 20;24(4):662-71.


Supplemental Content

Support Center